• Our BA-huMab® platform features the following advantages: Contains 30 human antibody κ light chain variable region genes, and 110 human antibody heavy chain variable region genes (IgM&IgG1); Directly generate human antibodies without need for humanization, which significantly accelerates antibody discovery process and decreases immunogenicity risk; Elicit an immune response quickly and produce a high antibody tier after immunization
• Our Phage display technology platform features the following advantages: efficient animal immunity technology, mature phage library construction technology, high-throughput and diverse phage based panning strategies, diverse evaluation capabilities for antibodies or antibody fragments

• High affinity with tumor target antigen by bivalent binding to achieve better drug efficacy
• Low affinity with T cells by monovalent binding to lower toxicity
• Reduces CD3 antibody binding affinity which significantly reduces the risk of CRS

• Design, synthesis and screening potential ADC linker-payload
• Identification of potential internalized antibodies
• Diverse antibody conjugation technologies
• Evaluation of ADC in vitro and in vivo
• Process development and quality analysis for ADC products

Non-Viral Gene Delivery Process Platform

• Free from virus research and production limitations, saving costs and development cycles
• The large load can accommodate multiple functional structural genes to achieve efficient transduction
• The population of stem-like cells is higher in proportion and more durable in vivo

4^th Gen CAR-T Technology

Enhanced CAR-T

• To overcome the limitations of the tumor microenvironment, multiple structures that enhance T cell function were selected

STEALTH^TM CAR-T

• Dual-target CAR kills antigenically heterogeneous tumors
• The function of "primary action CAR structure" and "secondary action CAR structure" is regulated to reduce the target risk

Non-Gene-Edited Universal CAR-T Technology

• The expression of TCR was down-regulated with "ReceptorTAC^TM" protein degradation technology
• Simple and efficient, CAR transduction and TCR down-regulation can be achieved in one step
• Good safety, no off-target risk associated with gene editing
• Developed with proprietary IP, the technology can be expanded to other cell therapy products